What SWK Holdings Corp does.

SWK Holdings Corporation (the “Company,” “we,” or “us”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Prior to September 30, 2025 our operations were comprised of two reportable segments: “Finance Receivables” and “Pharmaceutical Development.” As a result of the sale of substantially all assets of the Pharmaceutical Development segment, the Finance Receivables segment will be the only remaining operating segment in subsequent years. We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, “life sciences”). We allocate capital within our finance receivables portfolio in order to generate income through the sales of life science products by third parties and related earned income sources. The Company is headquartered in Dallas, Texas.

Revenue and profit, by fiscal year.

More on SWKHL.

• SWK Holdings Corp summary
• SWK Holdings Corp financial statements
• SWK Holdings Corp key metrics
• SWK Holdings Corp health scores and style box
• SWK Holdings Corp earnings
• SWK Holdings Corp dividends
• SWK Holdings Corp valuation
• SWK Holdings Corp ownership and insiders
• SWK Holdings Corp peers

Figures from SWK Holdings Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.